Interview 21 Apr 2021 Changing Attitudes on Vaccine and Public Health Investment The Covid-19 pandemic has pushed investment and research into vaccines and public health, but will such interest continue in the long term? Glenn Rockman, founder and Managing Partner of Adjuvant Capital, a VC firm investing in the infectious disease area, believes it will. Rockman did not plan to get into life science investment. With a […] April 21, 2021 - 5 minutesmins - By Helen Albert Share WhatsApp Twitter Linkedin Email
News and Trends 20 Apr 2021 Pandemic Boosts Diagnostics Field with High Revenues and Acquisitions The US medtech firm Hologic has bought the Finnish-French biotech Mobidiag for around €668M in the latest of a series of mergers, acquisitions, and stock market launches taking over the diagnostics market. Hologic’s move is the latest in a flurry of activity from the women’s health specialist, which has snapped up Diagenode in Belgium, Biotheranostics […] April 20, 2021 - 5 minutesmins - By Anita Chakraverty Share WhatsApp Twitter Linkedin Email
News and Trends 29 Oct 2020 Universal Flu Vaccines Yield Second Clinical Failure This Year In a blow to hopes for better protection from seasonal flu, last week’s phase III failure of BiondVax’s universal flu vaccine follows the phase II flop of Vaccitech’s flu vaccine in January. Last week proved a major setback for the Israeli biotech BiondVax. The company’s vaccine — designed to protect against multiple strains of flu […] October 29, 2020 - 5 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
In Depth 6 Jul 2020 How Immuno-Oncology Contributes to the Fight Against Covid-19 As the Covid-19 pandemic sweeps the world, cancer research is proving a valuable resource for developing new treatments for infectious diseases by harnessing the power of the immune system. Despite the growing number of viral outbreaks of different sizes and severity we have observed in the past years, the infectious disease market is far behind […] July 6, 2020 - 7 minutesmins - By Maya Chergova Share WhatsApp Twitter Linkedin Email
News and Trends 3 Feb 2020 CureVac Bids to Develop First mRNA Coronavirus Vaccine RNA vaccine developer CureVac will receive a grant of up to €8.3M from a global partnership to develop an mRNA vaccine against the new coronavirus strain from China. The agreement follows on from an existing collaboration launched in 2019, when the Coalition for Epidemic Preparedness Innovations, or CEPI, granted CureVac €30M to develop facilities that […] February 3, 2020 - 2 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
News and Trends 9 Jan 2020 Emergex Vaccines Secures €10M to Advance Synthetic Vaccine Development The UK biotech Emergex Vaccines has raised over €9.9M in a Series A funding round, which will allow it to progress the development of vaccines against diseases such as dengue, influenza, and Ebola to phase I clinical trials. Emergex specializes in the development of ‘set-point’ vaccines, which company CEO and co-founder Thomas Rademacher describes as […] January 9, 2020 - 3 minutesmins - By External Contributor Share WhatsApp Twitter Linkedin Email
News and Trends 3 Jan 2020 Update: CARB-X Grants Antabio Additional €4M to Develop Cystic Fibrosis Antibiotic Update (03/01/2020): The global non-profit partnership CARB-X has awarded Antabio €4M ($4.4M) as a second grant installment funding development of a novel antibiotic for use against Pseudomonas infections in patients with cystic fibrosis. This is the second installment of a grant worth up to €7.6M awarded to Antabio in 2017. The French biotech was awarded […] January 3, 2020 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 20 Dec 2019 Update: First Ever Ebola Vaccine Gets US and EU Approval Update (20/12/2019): After getting conditional approval in Europe in November, Merck has received FDA approval for its Ebola vaccine, the first to be approved in both regions. Published on 13/11/2019 The big pharma company Merck has won a conditional marketing authorization from the European Commission for the Ebola vaccine Ervebo, the first to be approved. […] December 20, 2019 - 2 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
News and Trends 25 Sep 2019 Danish Smallpox Vaccine Gets FDA Approval to Fight Bioterrorism A vaccine developed by the Danish company Bavarian Nordic has received FDA approval to prevent infections by monkeypox, as well as protect against the threat of a smallpox bioterror attack. This approval makes Bavarian Nordic’s vaccine the only approved vaccine in the world for preventing monkeypox, a rare viral infection that is similar to smallpox […] September 25, 2019 - 2 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
News and Trends 18 Sep 2019 Themis Raises €40M for First Phase III Trial of a Chikungunya Vaccine Vienna-based Themis Biosciences has raised €40M in a Series D round to fund a phase III trial that could lead to the approval of the world’s first vaccine for chikungunya infection. The round, one of the largest seen in Austrian biotech so far, was co-led by two new investors, Farallon Capital and Hadean Ventures. […] September 18, 2019 - 3 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 16 Sep 2019 Sepsis Diagnosed in 5 Minutes Instead of 24 Hours with Swiss Biotech’s Test A test for sepsis developed by the Swiss diagnostics company Abionic was able to predict within just five minutes which intensive care patients are likely to develop sepsis in a clinical study. In the pivotal study, Abionic trialed the blood test in 300 intensive care patients with a high risk of sepsis. Abionic found that […] September 16, 2019 - 3 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
News and Trends 20 Aug 2019 Nabriva Therapeutics Gets FDA Green Light for Pneumonia Antibiotic The US FDA has approved Nabriva Therapeutics’ Xenleta for treating community-acquired bacterial pneumonia, the first in a new class of antibiotics developed to treat this condition. Xenleta, also known as lefamulin, was discovered almost 10 years ago by Nabriva Therapeutics, a spinout company from Novartis split between Austria, Ireland and the US. The approval is […] August 20, 2019 - 3 minutesmins - By Helen Albert Share WhatsApp Twitter Linkedin Email